Professor, Obstetrics and Gynecology, University of Virginia School of Medicine
Obstetrics & Gynecology
Dr. Joann V. Pinkerton, MD
|
|
Give Review
Joann V. Pinkerton practices Obstetrics & Gynecology. She studied medicine at Virginia Commonwealth University School of Medicine. She has 2 awards "CMS Meaningful Use Stage 1 Certification" and "Fellow (FACOG)". Joann Pinkerton is a published doctor and has 83 publications published. The lastest was: 'Patient satisfaction with psychiatric treatment of menopausal women in a multidisciplinary women's midlife center.' She accepts Medicare.
Publications
- Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy.
- Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline.
- Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women.
- Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause.
- What are the concerns about custom-compounded "bioidentical" hormone therapy?
- Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence.
- Algorithm and mobile app for menopausal symptom management and hormonal/non-hormonal therapy decision making: a clinical decision-support tool from The North American ...
- Why the product labeling for low-dose vaginal estrogen should be changed.
- Perspectives on the first randomized sham-controlled trial of stellate ganglion block for hot flashes.
- Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.
- Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.
- Use of SERMs for treatment in postmenopausal women.
- Evaluation of the measurement model and clinically important differences for menopause-specific quality of life associated with bazedoxifene/conjugated estrogens.
- Osteoporosis treatment and prevention for postmenopausal women: current and future therapeutic options.
- Evaluation of the Efficacy and Safety of Bazedoxifene/Conjugated Estrogens for Secondary Outcomes Including Vasomotor Symptoms in Postmenopausal Women by Years Since M...
- Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause.
- Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial.
- Evaluation of the direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance using mediation modeling.
- Vulnerability to depression and cardiometabolic risk associated with early ovarian disruption.
- Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model.
- Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial.
- Risk of first-time heart disease higher for hormone therapy users with metabolic syndrome.
- Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens.
- Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial.
- Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause.
- Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controll...
- Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
- Atrofia vaginal.
- Vaginal atrophy.
- Pharmacological therapy for abnormal uterine bleeding.
- Reproductive aging, menopause, and health outcomes.
- Cervical cancer and human papillomavirus in indigenous Guyanese women.
- Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
- Menstrual cycle-related exacerbation of disease.
- Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.
- Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis.
- Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausa...
- Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.
- The need for evidence-based medicine to be integrated into clinical practice: role of the North American Menopause Society.
- Is there an association between vasomotor symptoms and both low bone density and cardiovascular risk?
- An expert offers advice on the use of unregulated, custom-compounded hormones.
- The effects of abuse on health problems in menopausal women.
- Combination therapy for treatment of osteoporosis: A review.
- Triple repeat diseases and unstable gonadal function.
- Perspective on menopausal vasomotor symptoms, CAM, and the SWAN.
- Why does NAMS need a code of ethics?
- Vasomotor symptoms in menopause: where we've been and where we're going.
- Acceptance of fragile X premutation genetic screening in women with ovarian dysfunction.
- Estrogen and cognition, with a focus on Alzheimer's disease.
- Reproduction in couples who are affected by human immunodeficiency virus: medical, ethical, and legal considerations.
- Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women.
- End-of-life discussions for the primary care obstetrician/gynecologist.
- Gamete retrieval in terminal conditions: is it practical? What are the consequences?
- Treatment of urogenital atrophy with low-dose estradiol: preliminary results.
- Tissue-selective estrogen complex bazedoxifene and conjugated estrogens for the treatment of menopausal vasomotor symptoms.
- Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women.
- Postmenopausal hormone therapy: an Endocrine Society scientific statement.
- Treatment of postmenopausal osteoporosis in a patient with celiac disease.
- MF-101, an estrogen receptor beta agonist for the treatment of vasomotor symptoms in peri- and postmenopausal women.
- Advances in the treatment of menopausal symptoms.
- Estrogen agonists/antagonists in combination with estrogen for prevention and treatment of menopause-associated signs and symptoms.
- Does addition of gabapentin to antidepressant therapy improve control of hot flashes?
- Medical Center Hour: teenage pregnancy.
- Dyskeratosis congenita with pancytopenia and horseshoe kidney.
- Ethical considerations of managed care.
- Intraamniotic 15(s)-15-methyl prostaglandin F2 alpha and termination of middle and late second-trimester pregnancy for genetic indications: a contemporary approach.
- Estradiol amplifies the amount of luteinizing hormone (LH) secreted in response to increasing doses of gonadotropin-releasing hormone by specifically augmenting the du...
- Resolving the clinical and ethical dilemma involved in fetal-maternal conflicts.
- Elective fetal reduction: the ultimate elective surgery.
- Parental rights at the birth of a near-viable infant: conflicting perspectives.
- Short-term cessation of hormone replacement therapy and improvement of mammographic specificity.
- Patient satisfaction with psychiatric treatment of menopausal women in a multidisciplinary women's midlife center.
- Alternatives to the use of estrogen in postmenopausal women.
- Cerebral arteriovenous malformation in pregnancy: presentation and neurologic, obstetric, and ethical significance.
- Ethical theory and principles: do they have any relevance to problems arising in everyday practice?
- Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
- Use of alternatives to estrogen for treatment of menopause.
- Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy.
- The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women.
- The Court and Webster: ethics, politics, and abortion--a panel discussion.
- Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement.
- Compounded non-FDA-approved menopausal hormone therapy prescriptions have increased: results of a pharmacy survey.
Schools
Virginia Commonwealth University School Of Medicine
University Va
Procedures Preformed
- Colposcopy
- Contraceptive Management
- Dilation and Curettage
- Fluid Contrast Ultrasound
- View All
Doctors Specialties
- Obstetrics
- Gynecology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACOG)
Education
-
University of Virginia -
Virginia Commonwealth University School of Medicine
Hospital
-
University of Virginia Medical Center
Drug Facts
| NPI NUMBER | 1437283801 | |
| NPPES Provider LastName | PINKERTON | |
| NPPES Provider FirstName | JOANN | |
| NPPES Provider ZIPCode | 229039353 | |
| NPPES Provider State | VA | |
| Specialty Description | Obstetrics/Gynecology | |
| Total Claim Count | 1730.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1437283801 |
| Last Name Of The Provider | PINKERTON |
| First Name Of The Provider | JOANN |
| View All |
Similar Doctors
|
Dr. Susan C. Modesitt, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Sarah S. Stadler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Virginia G. Barber, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jacqueline K. Halsey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kelly A. Owens, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carrie E. Sopata, MD
This Doctor is OpenDoctor Recommended.
|